Skip to main content
SpringerLink
Log in

ICD-Therapie zur Primär- und Sekundärprophylaxe kongenitaler arrhythmogener Erkrankungen

Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies

  • Schwerpunkt
  • Published:
Herzschrittmachertherapie + Elektrophysiologie Aims and scope Submit manuscript

Zusammenfassung

Angeborene elektrische und strukturelle Kardiomyopathien sind selten und mit einem erhöhten Risiko für Synkopen und den plötzlichen Herztod assoziiert. Aufgrund des jungen Alters der Betroffenen und der limitierten Datenlage stellt neben der Risikostratifikation auch die ICD-Therapie eine Herausforderung dar. In diesen jungen Patientenkollektiven ist die ICD-Therapie mit einer hohen Komplikationsrate assoziiert, die häufig eine primärprophylaktische ICD-Implantation nicht rechtfertigt. Ziel dieser Übersichtsarbeit ist es, die Risikostratifikation und ICD-Therapie verschiedener elektrischer und struktureller Kardiomyopathien zu beleuchten.

Abstract

Congenital electrical and structural cardiomyopathies are rare and associated with an increased risk for syncope and sudden cardiac death in the young. Due to the young age of the patients and the limited data available, risk stratification and especially ICD therapy are challenging. In this young patient collective, ICD therapy is associated with a high complication rate, which does not justify unreserved primary prophylactic ICD implantation. The aim of this review is to elucidate risk stratification and ICD therapy of various electrical and structural cardiomyopathies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Veltmann C, Schimpf R, Borggrefe M (2014) Idiopathic ventricular fibrillation. In: Cardiac electrophysiology: from cell to bedside, 6 ed. Elsevier, Philadelphia, S 967–973

    Book  Google Scholar 

  2. Priori SG, Wilde AA, Horie M et al (2013) Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace 15:1389–1406. doi:10.1093/europace/eut272

    Article  PubMed  Google Scholar 

  3. Brugada J, Brugada R, Antzelevitch C et al (2002) Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 105:73–78. doi:10.1161/hc0102.101354

    Article  PubMed  Google Scholar 

  4. Takagi M, Sekiguchi Y, Yokoyama Y et al (2014) Long-term prognosis in patients with Brugada syndrome based on Class II indication for implantable cardioverter-defibrillator in the HRS/EHRA/APHRS Expert Consensus Statement: multicenter study in Japan. Heart Rhythm 11:1716–1720. doi:10.1016/j.hrthm.2014.06.033

    Article  PubMed  Google Scholar 

  5. Olde Nordkamp LRA, Vink AS, Wilde AAM et al (2015) Syncope in Brugada syndrome: prevalence, clinical significance, and clues from history taking to distinguish arrhythmic from nonarrhythmic causes. Heart Rhythm 12:367–375. doi:10.1016/j.hrthm.2014.10.014

    Article  PubMed  Google Scholar 

  6. Probst V, Veltmann C, Eckardt L et al (2010) Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry. Circulation 121:635–643. doi:10.1161/CIRCULATIONAHA.109.887026

    Article  CAS  PubMed  Google Scholar 

  7. Priori SG, Gasparini M, Napolitano C et al (2012) Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol 59:37–45. doi:10.1016/j.jacc.2011.08.064

    Article  PubMed  Google Scholar 

  8. Okamura H, Kamakura T, Morita H et al (2015) Risk stratification in patients with brugada syndrome without previous cardiac arrest. Circ J 79:310–317. doi:10.1253/circj.CJ-14-1059

    Article  PubMed  Google Scholar 

  9. Conte G, Sieira J, Ciconte G et al (2015) Implantable cardioverter-defibrillator therapy in brugada syndrome: a 20-year single-center experience. J Am Coll Cardiol 65:879–888. doi:10.1016/j.jacc.2014.12.031

    Article  PubMed  Google Scholar 

  10. Brugada J, Brugada R, Brugada P (2003) Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 108:3092–3096. doi:10.1161/01.CIR.0000104568.13957.4F

    Article  PubMed  Google Scholar 

  11. Sacher F, Probst V, Maury P et al (2013) Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2. Circulation 128:1739–1747. doi:10.1161/CIRCULATIONAHA.113.001941

    Article  PubMed  Google Scholar 

  12. Veltmann C, Kuschyk J, Schimpf R et al (2010) Prevention of inappropriate ICD shocks in patients with Brugada syndrome. Clin Res Cardiol 99:37–44. doi:10.1007/s00392-009-0075-4

    Article  PubMed  Google Scholar 

  13. Conte G, Chierchia G-B, Wauters K et al (2014) Pulmonary vein isolation in patients with Brugada syndrome and atrial fibrillation: a 2-year follow-up. Europace 16:528–532. doi:10.1093/europace/eut309

    Article  PubMed  Google Scholar 

  14. Giustetto C, Cerrato N, Gribaudo E et al (2014) Atrial fibrillation in a large population with Brugada electrocardiographic pattern: prevalence, management, and correlation with prognosis. Heart Rhythm 11:259–265. doi:10.1016/j.hrthm.2013.10.043

    Article  PubMed  Google Scholar 

  15. Viskin S, Wilde AAM, Guevara-Valdivia ME et al (2013) Quinidine, a life-saving medication for Brugada syndrome, is inaccessible in many countries. J Am Coll Cardiol 61:2383–2387. doi:10.1016/j.jacc.2013.02.077

    Article  PubMed  Google Scholar 

  16. Nademanee K, Veerakul G, Chandanamattha P et al (2011) Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 123:1270–1279. doi:10.1161/CIRCULATIONAHA.110.972612

    Article  PubMed  Google Scholar 

  17. Hayashi M, Denjoy I, Extramiana F et al (2009) Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 119:2426–2434. doi:10.1161/CIRCULATIONAHA.108.829267

    Article  CAS  PubMed  Google Scholar 

  18. van der Werf C, Zwinderman AH, Wilde AAM (2012) Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. Europace 14:175–183. doi:10.1093/europace/eur277

    Article  PubMed  Google Scholar 

  19. Sherrid MV, Daubert JP (2008) Risks and challenges of implantable cardioverter-defibrillators in young adults. Prog Cardiovasc Dis 51:237–263. doi:10.1016/j.pcad.2008.10.001

    Article  PubMed  Google Scholar 

  20. Sy RW, Gollob MH, Klein GJ et al (2011) Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 8:864–871. doi:10.1016/j.hrthm.2011.01.048

    Article  PubMed  Google Scholar 

  21. Mohamed U, Gollob MH, Gow RM, Krahn AD (2006) Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm 3:1486–1489. doi:10.1016/j.hrthm.2006.08.018

    Article  PubMed  Google Scholar 

  22. Roses-Noguer F, Jarman JWE, Clague JR, Till J (2014) Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 11:58–66. doi:10.1016/j.hrthm.2013.10.027

    Article  PubMed  Google Scholar 

  23. Miyake CY, Webster G, Czosek RJ et al (2013) Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate. Circulation 6:579–587. doi:10.1161/CIRCEP.113.000170

    CAS  PubMed  Google Scholar 

  24. Schwartz PJ, Stramba-Badiale M, Crotti L et al (2009) Prevalence of the congenital long-QT syndrome. Circulation 120:1761–1767. doi:10.1161/CIRCULATIONAHA.109.863209

    Article  PubMed Central  PubMed  Google Scholar 

  25. Goldenberg I, Zareba W, Moss AJ (2008) Long QT syndrome. Curr Probl Cardiol 33:629–694. doi:10.1016/j.cpcardiol.2008.07.002

    Article  PubMed  Google Scholar 

  26. Schwartz PJ, Crotti L, Insolia R (2012) Long-QT syndrome: from genetics to management. Circulation 5:868–877. doi:10.1161/CIRCEP.111.962019

    PubMed Central  PubMed  Google Scholar 

  27. Abu-Zeitone A, Peterson DR, Polonsky B et al (2014) Efficacy of different beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol 64:1352–1358. doi:10.1016/j.jacc.2014.05.068

    Article  CAS  PubMed  Google Scholar 

  28. Chockalingam P, Crotti L, Girardengo G et al (2012) Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol 60:2092–2099. doi:10.1016/j.jacc.2012.07.046

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Moss AJ, Zareba W, SCHWARZ KQ et al (2008) Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 19:1289–1293. doi:10.1111/j.1540-8167.2008.01246.x

    Article  PubMed Central  PubMed  Google Scholar 

  30. Zareba W, Rosero S, Zeng D et al (2014) AB34-05: QTc shortening by GS-6615, a new late sodium current blocker, in LQT3 patients. Heart Rhythm 11:S81–S97. doi:10.1016/j.hrthm.2014.03.026

    Article  Google Scholar 

  31. Veltmann C, Schimpf R, Borggrefe M, Wolpert C (2009) Risk stratification in electrical cardiomyopathies. Herz 34:518–527. doi:10.1007/s00059-009-3288-4

    Article  PubMed  Google Scholar 

  32. Priori SG, Schwartz PJ, Napolitano C et al (2003) Risk stratification in the long-QT syndrome. N Engl J Med 348:1866–1874. doi:10.1056/NEJMoa022147

    Article  PubMed  Google Scholar 

  33. Goldenberg I, Mathew J, Moss AJ et al (2006) Corrected QT variability in serial electrocardiograms in long QT syndrome: the importance of the maximum corrected QT for risk stratification. J Am Coll Cardiol 48:1047–1052. doi:10.1016/j.jacc.2006.06.033

    Article  PubMed  Google Scholar 

  34. Locati EH, Zareba W, Moss AJ et al (1998) Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation 97:2237–2244

    Article  CAS  PubMed  Google Scholar 

  35. Zareba W, Moss AJ, Locati EH et al (2003) Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol 42:103–109. doi:10.1016/S0735-1097(03)00554-0

    Article  PubMed  Google Scholar 

  36. Zareba W, Moss AJ, Schwartz PJ et al (1998) Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 339:960–965. doi:10.1056/NEJM199810013391404

    Article  CAS  PubMed  Google Scholar 

  37. Barsheshet A, Goldenberg I, O-Uchi J et al (2012) Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation 125:1988–1996. doi:10.1161/CIRCULATIONAHA.111.048041

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Horner JM, Kinoshita M, Webster TL et al (2010) Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience. Heart Rhythm 7:1616–1622. doi:10.1016/j.hrthm.2010.08.023

    Article  PubMed  Google Scholar 

  39. Olde Nordkamp LRA, Wilde AAM, Tijssen JGP et al (2013) The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention. Circulation 6:91–100. doi:10.1161/CIRCEP.112.975268

    PubMed  Google Scholar 

  40. Schwartz PJ, Spazzolini C, Priori SG et al (2010) Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation 122:1272–1282. doi:10.1161/CIRCULATIONAHA.110.950147

    Article  PubMed  Google Scholar 

  41. Johnson JN, Tester DJ, Perry J et al (2008) Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm 5:704–709. doi:10.1016/j.hrthm.2008.02.007

    Article  PubMed Central  PubMed  Google Scholar 

  42. Giustetto C, Schimpf R, Mazzanti A et al (2011) Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 58:587–595. doi:10.1016/j.jacc.2011.03.038

    Article  PubMed  Google Scholar 

  43. Mazzanti A, Kanthan A, Monteforte N et al (2014) Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol 63:1300–1308. doi:10.1016/j.jacc.2013.09.078

    Article  PubMed Central  PubMed  Google Scholar 

  44. Gaita F, Giustetto C, Bianchi F et al (2003) Short QT Syndrome: a familial cause of sudden death. Circulation 108:965–970. doi:10.1161/01.CIR.0000085071.28695.C4

    Article  PubMed  Google Scholar 

  45. Schimpf R, Bauersfeld U, Gaita F, Wolpert C (2005) Short QT syndrome: successful prevention of sudden cardiac death in an adolescent by implantable cardioverter-defibrillator treatment for primary prophylaxis. Heart Rhythm 2:416–417. doi:10.1016/j.hrthm.2004.11.026

    Article  PubMed  Google Scholar 

  46. Schimpf R, Wolpert C, Bianchi F et al (2003) Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol 14:1273–1277. doi:10.1046/j.1540-8167.2003.03278.x

    Article  PubMed  Google Scholar 

  47. Wolpert C, Schimpf R, Giustetto C et al (2005) Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol 16:54–58. doi:10.1046/j.1540-8167.2005.04470.x

    Article  PubMed Central  PubMed  Google Scholar 

  48. Gaita F, Giustetto C, Bianchi F et al (2004) Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 43:1494–1499. doi:10.1016/j.jacc.2004.02.034

    Article  CAS  PubMed  Google Scholar 

  49. Basso C, Corrado D, Bauce B, Thiene G (2012) Arrhythmogenic right ventricular cardiomyopathy. Circulation 5:1233–1246. doi:10.1161/CIRCEP.111.962035

    PubMed  Google Scholar 

  50. Thiene G, Nava A, Corrado D et al (1988) Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 318:129–133. doi:10.1056/NEJM198801213180301

    Article  CAS  PubMed  Google Scholar 

  51. Marcus FI, Edson S, Towbin JA (2013) Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. J Am Coll Cardiol 61:1945–1948. doi:10.1016/j.jacc.2013.01.073

    Article  PubMed  Google Scholar 

  52. Marcus FI, McKenna WJ, Sherrill D et al (2010) Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 121:1533–1541. doi:10.1161/CIRCULATIONAHA.108.840827

    Article  PubMed Central  PubMed  Google Scholar 

  53. Zipes DP, Camm AJ, Borggrefe M et al (2006) ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8:746–837. doi:10.1093/europace/eul108

    Article  PubMed  Google Scholar 

  54. Hodgkinson KA, Parfrey PS, Bassett AS et al (2005) The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol 45:400–408. doi:10.1016/j.jacc.2004.08.068

    Article  PubMed Central  PubMed  Google Scholar 

  55. Schinkel AFL (2013) Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. Circulation 6:562–568. doi:10.1161/CIRCEP.113.000392

    PubMed  Google Scholar 

  56. Wichter T, Borggrefe M, Haverkamp W et al (1992) Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 86:29–37

    Article  CAS  PubMed  Google Scholar 

  57. Arbelo E, Josephson ME (2010) Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol 21:473–486. doi:10.1111/j.1540-8167.2009.01694.x

    Article  PubMed  Google Scholar 

  58. Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779. doi:10.1093/eurheartj/ehu284

    Article  PubMed  Google Scholar 

  59. Codd MB, Sugrue DD, Gersh BJ, Melton LJ (1989) Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 80:564–572

    Article  CAS  PubMed  Google Scholar 

  60. Maron BJ, Mathenge R, Casey SA et al (1999) Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 33:1590–1595

    Article  CAS  PubMed  Google Scholar 

  61. Qintar M, Morad A, Alhawasli H et al (2012) Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy. Cochrane Database Syst Rev 5:CD008523. doi:10.1002/14651858.CD008523.pub2

    PubMed  Google Scholar 

  62. Elliott PM, Gimeno JR, Thaman R et al (2006) Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 92:785–791. doi:10.1136/hrt.2005.068577

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. O’Mahony C, Jichi F, Pavlou M et al (2014) A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35:2010–2020. doi:10.1093/eurheartj/eht439

    Article  PubMed  Google Scholar 

  64. Maron BJ, Spirito P, Shen W-K et al (2007) Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298:405–412. doi:10.1001/jama.298.4.405

    CAS  PubMed  Google Scholar 

  65. Syska P, Przybylski A, Chojnowska L et al (2010) Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol 21:883–889. doi:10.1111/j.1540-8167.2009.01716.x

    PubMed  Google Scholar 

  66. Lambiase PD, Barr C, Theuns DAMJ et al (2014) Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J 35:1657–1665. doi:10.1093/eurheartj/ehu112

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rhythmologie und Elektrophysiologie, Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    D. Duncker, T. König, S. Hohmann &  C. Veltmann

Authors
  1. D. Duncker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. König
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Hohmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Veltmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Veltmann.

Ethics declarations

Interessenkonflikt

D. Duncker, T. König, S. Hohmann und C. Veltmann geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duncker, D., König, T., Hohmann, S. et al. ICD-Therapie zur Primär- und Sekundärprophylaxe kongenitaler arrhythmogener Erkrankungen. Herzschr Elektrophys 26, 82–93 (2015). https://doi.org/10.1007/s00399-015-0372-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00399-015-0372-8

Schlüsselwörter

Keywords

Search

Navigation